Iovance Biotherapeutics Announces Approval for TIL Therapy
The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
Copyright © 2014-2022 - AIM at Melanoma Foundation. All rights reserved. Website by RED ZEPHYR DESIGN